|
1) Fujimura Y, Matsumoto M, Yagi H, et al. von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Progress in Hematology. Int J Hematol. 2002; 75: 25-34
|
|
|
|
2) Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Eng J Med. 1998; 339: 1585-94
|
|
|
|
|
|
3) Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med. 1998; 339: 1578-84
|
|
|
|
|
|
4) George JN. The thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int. 2009; 75 (Suppl 112), S8-S10
|
|
|
|
|
|
5) Vesely SK, George JN, Lämmie B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102: 60-8
|
|
|
|
|
|
6) Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcomein patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004; 103: 4043-9
|
|
|
|
|
|
7) 藤村吉博, 松本雅則, 植村正人, 他. 動脈血栓症の制圧－VWF-GPIb軸依存性血小板血栓形成を調節するADAMTS13の基礎・臨床病態解析－. 最新医学. 2009; 64: 290-321
|
|
|
|
|
|
8) Levy GG, Nichols WC, Lian EC, et al. Mutations in member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001; 413: 488-94
|
|
|
|
|
|
9) Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol. Chem. 2001; 276: 41059-63
|
|
|
|
|
|
10) Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 2003; 102: 3232-7
|
|
|
|
|
|
11) Zheng X, Nishio K, Majerus EM, et al. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem. 2003; 278; 30136-41
|
|
|
|
|
|
12) Zhou W, Dong L, Ginsburg D, et al. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies. A novel therapeutic strategy？ J Biol Chem. 2005; 282: 39934-41
|
|
|
|
|
|
13) Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005; 106: 922-4
|
|
|
|
|
|
14) Manea M, Kristoffersson AC, Schneppenheim R, et al. Podocyte express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2007; 138: 651-62
|
|
|
|
|
|
15) Asada Y, Sumiyoshi A, Hayashi T, et al. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res. 1985; 38: 467-79
|
|
|
|
|
|
16) Tsai HM, Chandler WL, Sarode R, et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157: H7-associated hemolytic uremic syndrome. Pedatr Res. 2001; 49: 653-9
|
|
|
|
|
|
17) Feys HB, Deckmyn H, Vanhoorelbeke K. ADAMTS13 in health and disease. Acta Haematol. 2009; 21: 183-5
|
|
|
|
|
|
18) Loiat C, Girma JP, Desconclois C, et al. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol. 2009; 24: 19-29
|
|
|
|
|
|
19) 小亀浩市. VWF切断酵素ADAMTS13の遺伝子多型. Brain and Nerve. 2008; 60: 1325-32
|
|
|
|
|
|
20) Terrell DR, William LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005; 3: 1432-6
|
|
|
|
|
|
21) Sanchez-Luceros A, Farias CE, Amaral MM, et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and posy-delivery women. Thromn Haemost. 2004; 92: 1320-6
|
|
|
|
|
|
22) Bernardo A, Ball C, Nolasco L, et al. Effect of inflammatory cytokines on the release and cleavage of the endotherial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004; 104: 100-6
|
|
|
|
|
|
23) Ashida A, Nakamura H, Yoden A, et al. Successful treatment of a young infant who developed high-titer inhibitors against vWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw-Schulman syndrome. Am J Haematol. 2002; 71: 318-22
|
|
|
|
|
|
24) 芦田 明, 中倉兵庫, 松村英樹, 他. 治療経過中に抗ADAMTS13抗体価の奇異的上昇を認めたTTPの1女児例. 日本小児腎不全学会雑誌. in press
|
|
|
|
|
|
25) 金子仁臣, 松本雅則, 岡本浩平, 他. Rituximabとvincristineの併用が奏功した難治性血栓性血小板減少性紫斑病. 臨床血液. 2007; 48: 144-7
|
|
|
|
|
26) Yomtovian R, Niklinski W, Silver B, et al. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004; 124: 787-95
|
|
|
|
|
|
27) George JN, Woodson RD, Kiss JE, et al. Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the transfusion medicine/ hemostasis clinical trials network with a systemic review of rituximab therapy for immune-mediated disorders. J Clin Apheresis. 2006; 21: 49-56
|
|
|
|
|
|
28) Foley SR, Webert K, Arnold DM, et al. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney Int. 2009; 75(Suppl 112): S55- S58
|
|
|
|
|
|
29) Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int. 2009; 75(Suppl 112): S11-S14
|
|
|
|
|